Meta-analyses of pharmacological treatments rarely include information addressing primary study funding and conflicts of interest (COIs) of the authors for the included randomized control trials (RCTs), according to a study published in the March 9 issue of the Journal of the American Medical Association.
TUESDAY, March 8 (HealthDay News) -- Meta-analyses of pharmacological treatments rarely include information addressing primary study funding and conflicts of interest (COIs) of the authors for the included randomized control trials (RCTs), according to a study published in the March 9 issue of the Journal of the American Medical Association.
Michelle Roseman, from McGill University in Montral, and colleagues determined whether meta-analyses of pharmacological treatments in high-impact journals report COIs that are disclosed in the RCTs they include. Twenty-nine meta-analyses of patented pharmacological treatments published between January and October 2009 in five areas of medicine were reviewed to identify study funding disclosure, author financial relationships, and author employment for meta-analyses and their RCTs.
The researchers found that only two meta-analyses reported RCT funding sources, and none reported RCT author-industry relationships or pharmaceutical industry employment. The meta-analyses reviewed covered 509 RCTs, with 318 RCTs reporting funding sources, of which, 69 percent disclosed funding from industry. Of 132 RCTs that reported author financial disclosures, 69 percent had at least one author with a financial relationship to the pharmaceutical industry. In seven of the 29 meta-analyses, all of the included RCTs had at least one form of disclosed COI, but only one reported RCT funding sources, and none reported RCT author-industry ties or employment.
"This study found that meta-analyses of pharmacological interventions published in high-impact medical journals rarely reported the funding sources or author-industry financial ties of included RCTs, even when these sources of COIs were disclosed in RCT reports," the authors write.
One author disclosed a financial relationship with legal firms involved in cases dealing with the pharmaceutical industry.
Daré Bioscience initiates phase 3 clinical trial for ovaprene contraceptive
December 5th 2023Daré Bioscience has commenced a pivotal phase 3 clinical trial for ovaprene, an intravaginal contraceptive that releases a locally acting agent to prevent sperm entry into the cervical canal, marking a significant step towards a non-hormonal contraceptive option for women.
Read More
Exploring menstrual health: Insights from the Avon longitudinal study
December 5th 2023Unveiling a comprehensive analysis of menstrual cycle characteristics in mothers and daughters, this article delves into the diverse features, potential risk factors, and the importance of understanding these nuances for effective menstrual health management.
Read More
Integrating pharmacists into PPHTN management for enhanced blood pressure control
December 4th 2023A study reveals that involving pharmacists in the care of postpartum women at risk of persistently elevated blood pressure, as presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition, can provide an effective and feasible solution to managing hypertensive disorders, reducing postpartum readmission risks, and improving overall health care access.
Read More